Physician profile
David P Anto
NPI 1346227238
$13,827.08
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,537 · 2020: $3,003 · 2021: $3,271 · 2022: $2,270 · 2023: $1,582 · 2024: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,940.87 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $1,502.89 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,409.68 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $954.97 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $948.59 | 2019-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.69 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $657.97 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $624.55 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $600.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $584.10 | 2019-2023 | |
| Pfizer INC. | $520.02 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $437.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $375.83 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.27 | 2021-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $248.91 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Anto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.